Tubocurarine Chloride
Tubocurarine chloride is the chloride salt of tubocurarine, the prototype non-depolarizing neuromuscular blocking agent that competitively blocks nicotinic receptors at the motor end plate to produce reversible skeletal muscle paralysis. It was used as an anesthetic adjunct for surgical muscle relaxation and to facilitate endotracheal intubation. It has been superseded by agents with shorter duration, more predictable reversal, and fewer adverse effects.
分子量
681.6000 g/mol
TPSA
80.60 Ų
作用機序
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D構造
Cite this structure
Embed this structure
SMILES
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]
InChI
InChI=1S/C37H40N2O6.2ClH.5H2O/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33;;;;;;;/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41);2*1H;5*1H2/t28-,29+;;;;;;;/m0......./s1
Molecular Formula
C37H42Cl2N2O6
HBD / HBA
3 / 8
回転可能結合数
2
重原子数
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Tubocurarine chloride is the chloride salt of tubocurarine, the prototype non-depolarizing neuromuscular blocking agent that competitively blocks nicotinic receptors at the motor end plate to produce reversible skeletal muscle paralysis. It was used as an anesthetic adjunct for surgical muscle relaxation and to facilitate endotracheal intubation. It has been superseded by agents with shorter duration, more predictable reversal, and fewer adverse effects.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Tubocurarine Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989821. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16051918. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tubocurarine-chloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tubocurarine-chloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tubocurarine-chloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tubocurarine-chloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tubocurarine-chloride"></drugfyi-drug>